Meropenem

Meropenem

File:Meropenem.svg
Clinical data
Pregnancy category	B
Routes of administration	IV
ATC code	J01DH02 (WHO)
Legal status
Legal status	℞-only (U.S.)
Pharmacokinetic data
Bioavailability	100%
Protein binding	Approximately 2%.
Elimination half-life	1 hour
Excretion	Renal
Identifiers
IUPAC name 3-[5-(dimethylcarbamoyl) pyrrolidin-2-yl] sulfanyl-6- (1-hydroxyethyl)-4-methyl-7-oxo- 1-azabicyclo[3.2.0] hept-2-ene-2-carboxylic acid
CAS Number	119478-56-7
PubChem CID	64778
DrugBank	APRD01097
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C17H25N3O5S
Molar mass	383.464 g/mol

WikiDoc Resources for Meropenem
Articles
Most recent articles on Meropenem Most cited articles on Meropenem Review articles on Meropenem Articles on Meropenem in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Meropenem Images of Meropenem Photos of Meropenem Podcasts & MP3s on Meropenem Videos on Meropenem
Evidence Based Medicine
Cochrane Collaboration on Meropenem Bandolier on Meropenem TRIP on Meropenem
Clinical Trials
Ongoing Trials on Meropenem at Clinical Trials.gov Trial results on Meropenem Clinical Trials on Meropenem at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Meropenem NICE Guidance on Meropenem NHS PRODIGY Guidance FDA on Meropenem CDC on Meropenem
Books
Books on Meropenem
News
Meropenem in the news Be alerted to news on Meropenem News trends on Meropenem
Commentary
Blogs on Meropenem
Definitions
Definitions of Meropenem
Patient Resources / Community
Patient resources on Meropenem Discussion groups on Meropenem Patient Handouts on Meropenem Directions to Hospitals Treating Meropenem Risk calculators and risk factors for Meropenem
Healthcare Provider Resources
Symptoms of Meropenem Causes & Risk Factors for Meropenem Diagnostic studies for Meropenem Treatment of Meropenem
Continuing Medical Education (CME)
CME Programs on Meropenem
International
Meropenem en Espanol Meropenem en Francais
Business
Meropenem in the Marketplace Patents on Meropenem
Experimental / Informatics
List of terms related to Meropenem

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem® and Meronem®. Other brand names include Mepem® (Taiwan) and Meropen® (Japan, Korea). It gained FDA approval in July 1996. It penetrates well into many tissues and body fluids including the cerebrospinal fluid, bile, heart valves, lung, and peritoneal fluid.

Mechanism of action

Meropenem is bactericidal except against Listeria monocytogenes where it is bacteriostatic. It inhibits bacterial wall synthesis like other beta-lactam antibiotics. In contrast to other beta-lactams, it is highly resistant to degradation by beta-lactamases or cephalosporinases. Resistance generally arises due to mutations in penicillin binding proteins, production of metallo-beta-lactamases, or resistance to diffusion across the bacterial outer membrane. Unlike imipenem, it is stable to dehydropeptidase-1 and can therefore be given without cilastatin.

Indications

The spectrum of action includes many gram-positive and gram-negative bacteria and even some anaerobic bacteria. The overall spectrum is similar to imipenem although meropenem is more active against Enterobacteriaceae and less active against gram-positive bacteria. It is also very resistant to extended-spectrum beta lactamases but may be more susceptible to metallo-beta-lactamases. However, meropenem should not be used to treat MRSA infections.

Administration

Meropenem must be administered intravenously. It is supplied as a white crystalline powder to be dissolved in 5% monobasic potassium phosphate solution.

Common adverse effects

The most common adverse effects are diarrhea (4.8%), nausea and vomiting (3.6%), injection-site inflammation (2.4%), headache (2.3%), rash (1.9%), and thrombophlebitis (0.9%). Many of these adverse effects were observed in the setting of severely ill individuals who were already taking many medications. Meropenem also has a reduced potential for causing seizures in comparison with imipenem.